Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
Dr. Nils Krüger, a researcher at Harvard Medical School who has studied GLP-1s, said that it is the first time he can recall that the general public knows so much about a drug.
Simplified Text
Dr. Nils Krüger, a Harvard Medical School researcher who studied GLP-1s, stated that it is the first time he can recall the general public knowing so much about a drug.
Confidence Score
1.000
Claim Maker
Dr. Nils Krüger
Context Type
News Article
Context Details
{
    "date": "2026-09-22",
    "person": "Dr. Nils Kr\u00fcger",
    "affiliation": "Harvard Medical School"
}
Subject Tags
Drugs GLP-1 Public Awareness
UUID
ea18dc2f-4cc4-471b-bbf0-ef50fac352f6
Vector Index
✗ No vector
Created
September 25, 2026 at 10:06 AM (2 weeks ago)
Last Updated
September 25, 2026 at 10:06 AM (2 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/22/well/ozempic-glp1-medical-reason.html
GLP-1 Prescriptions for People With No Medical Need Are Climbing
Completed News
7 claims
2 weeks ago
https://nytimes.com/2026/09/22/well/ozempic-glp1-medical-reason.html

A new study analyzing over 92 million U.S. adult medical records found more than 1.1 million people taking GLP-1 medications without an apparent medical reason like obesity or diabetes. Doctors express concern over off-label use, potential risks, and the cultural phenomenon surrounding these drugs.

GLP-1 drugs Ozempic Off-label prescriptions Weight loss drugs Medical ethics Public health Obesity Diabetes

Similar Claims (5)

Other claims identified as semantically similar to this one.